Team Medical Affairs News Contact

Team Medical Affairs News Contact

Back

Angiotensin II for the treatment of distributive shock in the intensive care unit: A US costeffectiveness analysis

March 2, 2020

A subsidiary of Innoviva, Inc.

Innoviva is a diversified holding company with a portfolio of royalties and other healthcare assets. Learn more at inva.com

Privacy Policy | Terms of Use

Team Medical Affairs News Contact

A subsidiary of Innoviva, Inc.

Innoviva is a diversified holding company with a portfolio of royalties and other healthcare assets. Learn more at inva.com

Privacy Policy | Terms of Use

© 2023 INNOVIVA SPECIALTY THERAPEUTICS | ALL RIGHTS RESERVED